Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Immunocore Holdings (IMCR) over the last 3 years, with Q3 2025 value amounting to $6.0 million.

  • Immunocore Holdings' Change in Receivables rose 17322.08% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 5006.34%. This contributed to the annual value of $12.3 million for FY2024, which is 3090.48% down from last year.
  • Immunocore Holdings' Change in Receivables amounted to $6.0 million in Q3 2025, which was up 17322.08% from $4.2 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Change in Receivables peaked at $10.2 million during Q4 2023, and registered a low of -$836000.0 during Q1 2025.
  • Over the past 3 years, Immunocore Holdings' median Change in Receivables value was $3.6 million (recorded in 2023), while the average stood at $3.6 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 36539.28% in 2024, then plummeted by 11348.82% in 2025.
  • Immunocore Holdings' Change in Receivables (Quarter) stood at $10.2 million in 2023, then tumbled by 87.33% to $1.3 million in 2024, then soared by 362.47% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, $4.2 million for Q2 2025, and -$836000.0 during Q1 2025.